Skip to content

Clinical trials

Demyelinating Diseases trials in France

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Demyelinating Diseases Country / region: France Clear all

15 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20091
20103
20131
20152
20171
20192
20201
20221
20231
20241
20251

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed8
Terminated4
Unknown status2
Recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
University Hospital, Bordeaux2
University Hospital, Lille2
Alexion Pharmaceuticals, Inc.1
Assistance Publique - Hôpitaux de Paris1
Baxalta now part of Shire1
Boston Scientific Corporation1
EMD Serono1
Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecul1
Fondation Ophtalmologique Adolphe de Rothschild1
Hospices Civils de Lyon1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Demyelinating Diseases15
Multiple Sclerosis7
Nervous System Diseases6
Immune System Diseases5
Optic Neuritis5
Autoimmune Diseases of the Nervous System4
Autoimmune Diseases3
Multiple Sclerosis, Relapsing-Remitting3
Cognitive Dysfunction2
Demyelinating Autoimmune Diseases, CNS2

Trials

Showing 26 to 15 of 15. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.